A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Clinical trial NCT06136559 · RECRUITING
Trial details
- NCT number
- NCT06136559
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-13
- Primary completion
- 2032-09-07
- Enrollment
- 1200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.